

•

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/918,637	08/01/2001	Ahmed Jehanli	01246.0134	2644
75	590 12/10/2002			
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 1300 I Street, N.W.			EXAMINER	
			HINES, JANA A	
Washington, DC 20005-3315				
			ART UNIT	PAPER NUMBER
			1645	~
			DATE MAILED: 12/10/2002	1

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/918,637	JEHANLI ET AL.			
		Examiner	Art Unit			
		Ja-Na A Hines	1645			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ —	Responsive to communication(s) filed on <u>01 August 2001</u> .					
2a) <u></u> —	This action is FINAL . 2b) ☐ Thi	is action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠	Claim(s) 1-21 is/are pending in the application	,				
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)□	Claim(s) is/are allowed.					
6)□	6) Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
	Claim(s) <u>1-21</u> are subject to restriction and/or e	election requirement.				
Applicati	on Papers	, ·				
9)☐ The specification is objected to by the Examiner.						
10)[]	The drawing(s) filed on is/are: a)□ accep	•				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	The proposed drawing correction filed on		oved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 						
Attachment(s)						
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/918,637

Art Unit: 1645

DETAILED ACTION

Election/Restrictions

This application contains claims directed to the following patentably distinct species of the claimed invention: Claim 2 is drawn to drug conjugates wherein the drug is chosen from the patentably distinct subgeneric species: protein, peptide, polyamine, ceramide, alkyl chain or carbohydrate. If applicants elect any one of the above subgenerics, then applicants are requested to elect a single disclosed species from within the subgeneric. For example if applicants elect protein then applicants are requested to elect one of the following: rabbit serum albumin, bovine serum albumin, ovalbumin, gamma globulin and thyro globulin. It is noted that the subgenerics are patentably distinct because each has a distinct structure, for example, a peptide has peptide bonds however the other subgeneric species does not have such bonds.

Claim 6 is drawn to drugs wherein the drug is chosen from the patentably distinct subgeneric species: antihypertensive, antiviral, antimicrobial, antifungal, anti-inflammatory, antitumour, psychopharmaceutical agents including corticosteroids, mono- to oligosaccharides, vitamins, provitamins and hormones. If applicants elect any one of the above subgenerics, then applicants are requested to elect a single disclosed species from within the subgeneric. For example if applicants elect antihypertensive then applicants are requested to elect one of the following: lisinopril, amilodipine or captopril. It is noted that the subgenerics are patentably distinct because each has a distinct structure and distinct uses.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 4-5, 7, 9-21 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 09/918,637 Page 4

Art Unit: 1645

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ja-Na Hines whose telephone number is 703-305-0487. The examiner can normally be reached on Monday-Thursday and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on 703-308-3909. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Ja-Na Hines 96 December 9, 2002

LYNETTE R. E. SMITH
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600